Integer Holdings Corporation in the news

Integer Holdings Corporation is being acquired for USD 4.4 billion at USD 127.00 per share, and a consensus price target is USD 109.86 as of October 8, 2026.

Integer Holdings Corporation's stock may experience significant price movement, according to options market indicators, despite a 'Hold' rating from analysts.

Bronstein, Gewirtz & Grossman, LLC is investigating Integer Holdings Corporation for potential corporate wrongdoing, focusing on investors who held shares before July 25, 2024.

Integer (ITGR) is a better investment than Biodesix (BDSX) based on 11 out of 17 comparative factors.

Integer Holdings Corporation's 2.125% Convertible Senior Notes due 2028 are now convertible by holders from October 1 to December 31, 2026, due to the company's stock price performance.

Integer Holdings Corporation shows neutral near and mid-term readings, is testing resistance, and has an exceptional short setup.

Integer Holdings Corporation's 2.125% Convertible Senior Notes due 2028 are now convertible into cash or common stock at the holders' option until December 31, 2026, due to a sustained rise in the company's stock price.

Integer Holdings cleared a key U.S. regulatory hurdle for its $5.7 billion acquisition by KKR-managed funds, with shareholder approval pending.

Integer Holdings Corporation received early termination of the Hart-Scott-Rodino waiting period for its pending $5.7 billion acquisition by KKR.

Integer Holdings Corporation manufactures medical devices, including products for cardiology, neuromodulation, and surgery, serving original equipment manufacturers globally.

Integer Holdings Corporation is being acquired by KKR, with its recent financial performance showing mixed results due to new product adoption challenges, despite overall stock outperformance.

Integer Holdings Corporation's stock rose after a proposed KKR acquisition at USD 127.00 per share was announced, despite a revenue decline and leverage concerns.

Integer Holdings Corporation is a medical device contract development and manufacturing company that provides products for various medical fields and original equipment manufacturers worldwide.

Bronstein, Gewirtz & Grossman, LLC is investigating Integer Holdings Corporation for potential corporate wrongdoing and encouraging investors to join the inquiry.

Integer Holdings, a medical device outsource manufacturer, exceeded Q2 revenue and EPS estimates despite a slight year-over-year revenue decrease, leading to a 4.1% stock increase.

Kahn Swick & Foti, LLC is investigating the proposed sale of Integer Holdings Corporation to KKR for potential undervaluation.

A law firm is investigating Integer Holdings Corporation for potential corporate wrongdoing, encouraging investors who purchased shares before July 25, 2024, to participate.

Integer Holdings Corporation's stock is trading just below KKR's proposed USD 127 per share cash acquisition price, with a legal review ongoing.

The analysis of Integer Holdings Corporation (ITGR) indicates neutral near- and mid-term readings, no clear price positioning, and compelling upside potential due to the absence of resistance levels above the current price.

Integer Holdings Corporation, a medical device contract manufacturer, is trading near its 52-week high, demonstrating strong cash flow despite recent revenue contraction and mixed analyst sentiment.